Pharmaceutical Industry Articles & Reports - Page 44

Examine the role of AI in Health Information Exchange (HIE), including TEFCA growth, FHIR mandates, data standardization, security, predictive analytics, and ethical considerations as of 2026.

This article explains the core functions of LIMS for sample management, data integrity, and regulatory compliance, and provides a comparative analysis of top systems.

Learn methods for integrating ChatGPT with private enterprise data using Microsoft Azure and Microsoft Foundry. Covers security controls, compliance, Azure OpenAI Service, agents, MCP, and agentic retrieval.

Learn about the FDA Adverse Event Reporting System (FAERS), now updated in real time with over 31 million reports, for post-marketing drug safety surveillance, signal detection, and AI-enhanced pharmacovigilance.

Comprehensive guide to Software as a Medical Device (SaMD): IMDRF definition, FDA QMSR and PCCP frameworks, EU MDR/AI Act compliance, real-world examples, and 2025-2026 regulatory updates.

This article defines open-source LIMS and details its core functions, such as sample registration, data collection, quality control, and workflow management. Updated for 2026 with SENAITE 2.6.0, LabKey 25.11, OpenELIS AI features, FDA CSA guidance, and current market data.

Learn about Clinical Decision Support (CDS) systems, from early rule-based expert systems to modern data-driven models powered by artificial intelligence. Updated for 2026 with the latest FDA clearances, EU AI Act implementation, and industry developments.

An overview of the healthcare revenue cycle, a financial process covering all administrative and clinical functions from patient scheduling to payment collection.

Comprehensive review of global Health Management Information Systems (HMIS), covering major platforms (Epic, Oracle Health, DHIS2, OpenMRS, OpenEMR), AI integration, cloud adoption, interoperability standards, and 2025-2026 developments.

An explanation of Clinical Data Management (CDM) and its function in research. Learn how CDM ensures high-quality, reliable data for clinical trials.

Profiles of leading US researchers and industry pioneers applying generative AI to pharmaceutical R&D, drug discovery, protein design, and clinical trials – updated with 2025-2026 milestones including Phase II/III results, major funding rounds, and regulatory breakthroughs.

An analysis of AI adoption trends in U.S. hospitals through 2025-2026. Examines clinical and operational use cases including ambient AI scribes, Epic's new AI tools, FDA regulatory updates, and ethical considerations in healthcare.

A comprehensive guide to pharmaceutical KPIs for quality, compliance, and operational excellence. Covers metrics for R&D, clinical trials, manufacturing, supply chain, and pharmacovigilance, updated with 2025-2026 regulatory developments including FDA QMM, ICH E6(R3), and ISO 9001:2026.

An analysis of large language model (LLM) diagnostic performance compared to physicians, covering GPT-4o, MedGemma, meta-analyses on LLM-assisted diagnosis, patient trust surveys, and 2025-2026 regulatory developments.

An analysis of the 2025 healthcare administration job market. Examines key trends, demand drivers, worker shortages, and BLS employment projections.

An analysis of the core technologies and design philosophies of Wolfram Alpha (symbolic AI) and ChatGPT (generative AI), detailing their key differences. Updated for GPT-5.2, Wolfram Language 14.3, and the transition from plugins to Custom GPTs.

Learn about AHIP certification, the standard for Medicare agents. Updated for 2026 with current costs, NABIP alternative, IRA impacts, and Medicare Advantage market trends.

Examines the top 10 programming languages by usage and popularity in the context of AI-assisted coding, analyzing AI tool support (Copilot, Cursor, Claude Code, Amazon Q Developer) and ecosystem maturity with 2025-2026 data.

Learn about mechanistic interpretability, named an MIT 2026 Breakthrough Technology. Covers circuit tracing, sparse autoencoders, attribution graphs, and how researchers are reverse-engineering AI models to uncover causal mechanisms within neural networks.

An educational profile of ZUSDURI, a mitomycin hydrogel for intravesical chemoablation of low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). Updated with 2026 J-code reimbursement, UGN-103 UTOPIA trial results, and commercial launch data.

This article explains how pill identifier software improves patient safety by accurately identifying medication using physical traits, AI-powered image recognition, and deep learning models achieving over 96% accuracy, preventing costly medical errors.

An analysis of the Medicare program in 2025, detailing the structure and the significant policy impacts of the One Big Beautiful Bill Act (P.L. 119-21).

Examine 2025 trends for Contract Sales Organizations in pharma. This analysis compares top providers and strategies for HCP engagement and outsourcing.

Examines the evolution of eCTD systems from specialized publishers for regulatory submissions to enterprise platforms that serve as a unified drug lifecycle archive, including the impact of eCTD v4.0, AI-powered RIM tools, and IDMP compliance.